Blocking APOC1 Slows Lymphoma Cell Growth

A Fresh Approach to Treating Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma (NHL), a group of cancers that affect the lymphatic system. This disease accounts for nearly 30–40% of all adult NHL cases worldwide and presents significant challenges in treatment due to its biological complexity. DLBCL can develop in lymph nodes or other organs, and in many cases, it progresses rapidly. Some patients respond well to standard treatments, but others face high relapse rates or resistance to therapy, making it difficult to achieve long-term remission.

The current first-line treatment for DLBCL is R-CHOP therapy, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. While this regimen has improved patient survival, 30–40% of cases either do not respond to treatment or relapse after an initial response. This highlights the urgent need for new therapeutic targets that can improve outcomes, particularly for patients with aggressive or treatment-resistant disease. Scientists are now focusing on understanding the molecular drivers of DLBCL to identify new ways to attack the cancer. A recent study has uncovered Apolipoprotein C1 (APOC1) as a promising target, offering fresh hope for innovative treatment strategies.

What Is APOC1, and Why Does It Matter?

APOC1 is a small protein that plays a well-known role in fat metabolism, helping regulate how the body processes and transports lipids. However, growing evidence suggests that APOC1 is also involved in cancer progression, particularly in aggressive malignancies. Researchers analyzing patient tissue samples and data from The Cancer Genome Atlas (TCGA) discovered that APOC1 levels are significantly higher in DLBCL tumors compared to normal tissues. Moreover, they found a direct correlation between elevated APOC1 levels and poor patient survival rates, indicating that APOC1 may contribute to disease progression.

Further investigations revealed that APOC1 is more than just a passive biomarker—it plays an active role in sustaining cancer cell survival. When researchers used gene-silencing techniques to reduce APOC1 levels in DLBCL cells, they observed significant changes: the lymphoma cells became more vulnerable, stopped multiplying, and entered apoptosis (programmed cell death). This suggests that blocking APOC1 could directly weaken the disease, making it a potential new target for treatment. These findings mark an important step toward developing therapies that not only kill cancer cells but also prevent the aggressive growth and spread of DLBCL.

Stopping Tumor Growth and Cutting Off Its Blood Supply

Cancer cells don’t just grow on their own—they need a network of blood vessels to bring in oxygen and nutrients. This process, called angiogenesis, allows tumors to survive and spread. The study found that APOC1 plays a major role in driving angiogenesis in DLBCL.

When researchers blocked APOC1:

• Lymphoma cells stopped dividing and began to die
• Tumor growth slowed down in laboratory models
• The formation of new blood vessels within tumors was reduced

One key finding was that APOC1 helps produce VEGFA (vascular endothelial growth factor A), a protein that stimulates blood vessel growth. When APOC1 was removed, VEGFA levels dropped, making it harder for the tumor to build a blood supply.

This means that targeting APOC1 could provide a dual benefit: slowing tumor growth while also cutting off its access to essential nutrients, making the cancer more vulnerable to other treatments.

How This Could Change Lymphoma Treatment

These findings suggest that APOC1 could be a new target for future treatments. Right now, there are no drugs specifically designed to block APOC1, but scientists are exploring potential ways to do so.

Future treatment strategies could include:

• Developing drugs to block APOC1, stopping cancer growth at its source
• Using APOC1 levels as a diagnostic tool, helping doctors predict which patients might have aggressive disease
• Combining APOC1 blockers with existing treatments, making chemotherapy and immunotherapy more effective

This could be especially beneficial for patients whose cancer has stopped responding to current therapies or who have high APOC1 levels, indicating a more aggressive form of the disease.

What’s Next?

While this research provides exciting insights, more studies are needed to confirm how APOC1-targeted treatments might work in real patients. Scientists are now focusing on developing drugs that could block APOC1 safely and effectively.

By uncovering APOC1’s role in DLBCL, this study marks an important step toward more effective and personalized treatments. As researchers continue to explore this target, blocking APOC1 could become a powerful new tool in the fight against lymphoma.

 

The translation of the preceding English text in Chinese:

 

一种治疗弥漫性大B细胞淋巴瘤（DLBCL）的新方法

弥漫性大B细胞淋巴瘤（DLBCL）是最常见且最具侵袭性的非霍奇金淋巴瘤（NHL）类型之一。非霍奇金淋巴瘤是一类影响淋巴系统的癌症。DLBCL约占全球所有成人NHL病例的30%至40%，由于其生物学复杂性，在治疗上面临重大挑战。DLBCL可以发生在淋巴结或其他器官，且在许多病例中病情进展迅速。部分患者对标准治疗反应良好，但也有患者面临高复发率或对治疗产生耐药，使得长期缓解变得困难。

目前DLBCL的一线治疗是R-CHOP方案，即利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松的联合治疗。虽然该方案提高了患者的生存率，但仍有30%至40%的患者对治疗无反应或在初次反应后复发。这凸显了亟需寻找新的治疗靶点，以改善治疗效果，尤其是对于具有高度侵袭性或耐药性的患者。科学家们正致力于了解DLBCL的分子驱动机制，从而找到攻击癌细胞的新方法。一项最新研究发现载脂蛋白C1（APOC1）是一个有前景的治疗靶点，为创新疗法带来了新的希望。

什么是APOC1，它为什么重要？

APOC1是一种小分子蛋白，已知在脂类代谢中发挥重要作用，有助于调节机体对脂质的处理和运输。然而，越来越多的证据表明，APOC1也参与癌症的发展，尤其是在高度恶性的肿瘤中。研究人员通过分析患者组织样本及癌症基因组图谱（TCGA）数据发现，DLBCL肿瘤中的APOC1水平显著高于正常组织。此外，他们还发现，APOC1水平升高与患者较差的生存率之间存在直接相关性，提示APOC1可能促进疾病进展。

进一步研究表明，APOC1不仅是一个被动的生物标志物，还在维持癌细胞存活方面起着积极作用。当研究人员利用基因沉默技术降低DLBCL细胞中的APOC1水平时，观察到显著变化：淋巴瘤细胞变得更脆弱，停止增殖并进入程序性细胞死亡（凋亡）。这表明抑制APOC1可能直接削弱疾病，为治疗提供了一个新的潜在靶点。这些发现标志着向开发能够同时杀死癌细胞并防止DLBCL侵袭性扩散的疗法迈出了重要一步。

抑制肿瘤生长并切断其血液供应

癌细胞不仅仅是自行生长——它们还需要一套血管网络来提供氧气和营养。这一过程称为血管生成，它使得肿瘤能够生存并扩散。研究发现，APOC1在DLBCL中推动血管生成过程中起着关键作用。

当研究人员阻断APOC1后：

• 淋巴瘤细胞停止分裂并开始死亡

• 实验模型中的肿瘤生长速度减慢

• 肿瘤内新血管的形成减少

其中一个关键发现是，APOC1促进血管内皮生长因子A（VEGFA）的生成，而VEGFA是一种刺激血管生长的重要蛋白。当APOC1被抑制后，VEGFA水平下降，肿瘤构建血液供应的能力受限。

这意味着，靶向APOC1可带来双重好处：减缓肿瘤生长，同时切断其获取必需营养的途径，使癌细胞对其他治疗方法更加敏感。

这可能如何改变淋巴瘤治疗

这些研究结果表明，APOC1可能成为未来治疗的新靶点。目前还没有专门设计用来阻断APOC1的药物，但科学家们正探索潜在的开发途径。

未来的治疗策略可能包括：

• 开发靶向阻断APOC1的药物，从源头抑制癌症发展

• 将APOC1水平作为诊断工具，帮助医生预测哪些患者可能患有更具侵袭性的疾病

• 将APOC1抑制剂与现有治疗方法联合使用，提升化疗和免疫治疗的疗效

这对那些对现有治疗反应不佳或具有高APOC1水平、病情更为严重的患者尤其有益。

接下来会发生什么？

虽然这项研究提供了令人振奋的新见解，但仍需进一步研究以确认针对APOC1的治疗在真实患者中的有效性。科学家们目前正专注于开发既安全又有效的APOC1抑制药物。

通过揭示APOC1在DLBCL中的作用，这项研究为更有效和个性化的治疗方案奠定了基础。随着研究的深入，阻断APOC1有望成为抗击淋巴瘤的重要新武器。

---

Reference:

Jing Gao, Xiaojuan Lu, Guanglei Wang, Tanling Huang, Zhongyu Tuo, Weiwei Meng

APOC1 knockdown induces apoptosis and decreases angiogenesis in diffuse large B-cell lymphoma cells through blocking the PI3K/AKT/mTOR pathway.

Biomol Biomed [Internet]. 2025 Jan. 23 [cited 2025 Mar. 25];

Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/11550

---

And don’t forget!

We invite submissions for our upcoming thematic issues, including:

• Immune Prediction and Prognostic Biomarkers in Immuno-Oncology
• Artificial Intelligence and Machine Learning in disease diagnosis and treatment target identification
• Insulin for Type 1 and Type 2 Diabetes Mellitus: Pathophysiology, Complications and Treatment
• Cell-based Therapeutics

More news: Blog

Editor: Merima Hadžić